Germany-based molecular diagnostics company Curetis has extended its series B round to €27m ($33.7m) after securing funding from drugs company Roche and molecular biology specialist Qiagen.
The second tranche totalled approximately $18.1m, $8.7m of which was provided by Qiagen and healthcare insurer Achmea, which participated via its LSP Health Economics Fund, formed with Life Sciences Partners in February 2012.
The other $9.4m was supplied by Roche, which participated through its Roche Venture Fund unit; investment firm HBM Partners, which led…